First Quadrant L P CA raised its position in Chemed Corp. (NYSE:CHE) by 0.9% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 36,951 shares of the company’s stock after buying an additional 328 shares during the period. First Quadrant L P CA owned approximately 0.23% of Chemed Corp. worth $7,558,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in the company. Aperio Group LLC raised its position in Chemed Corp. by 7.0% in the second quarter. Aperio Group LLC now owns 15,545 shares of the company’s stock worth $3,179,000 after buying an additional 1,011 shares during the period. Nisa Investment Advisors LLC increased its stake in shares of Chemed Corp. by 0.4% in the second quarter. Nisa Investment Advisors LLC now owns 11,600 shares of the company’s stock worth $2,373,000 after buying an additional 50 shares during the period. Cape Cod Five Cents Savings Bank increased its stake in shares of Chemed Corp. by 19.9% in the second quarter. Cape Cod Five Cents Savings Bank now owns 5,511 shares of the company’s stock worth $1,127,000 after buying an additional 916 shares during the period. State of Alaska Department of Revenue increased its stake in shares of Chemed Corp. by 75.6% in the second quarter. State of Alaska Department of Revenue now owns 3,179 shares of the company’s stock worth $650,000 after buying an additional 1,369 shares during the period. Finally, NN Investment Partners Holdings N.V. bought a new stake in shares of Chemed Corp. during the second quarter worth about $383,000. 97.78% of the stock is owned by hedge funds and other institutional investors.
Chemed Corp. (CHE) traded up 0.74% during mid-day trading on Wednesday, hitting $191.17. The stock had a trading volume of 65,425 shares. Chemed Corp. has a 52-week low of $130.05 and a 52-week high of $216.01. The firm has a 50-day moving average of $200.36 and a 200-day moving average of $192.63. The stock has a market cap of $3.06 billion, a P/E ratio of 47.42 and a beta of 1.14.
Chemed Corp. (NYSE:CHE) last released its earnings results on Tuesday, July 25th. The company reported $2.15 EPS for the quarter, topping analysts’ consensus estimates of $1.89 by $0.26. Chemed Corp. had a net margin of 4.16% and a return on equity of 26.18%. The business had revenue of $415.06 million for the quarter, compared to the consensus estimate of $407.56 million. During the same period in the previous year, the firm earned $1.80 EPS. The business’s revenue for the quarter was up 6.3% on a year-over-year basis. On average, analysts forecast that Chemed Corp. will post $8.20 EPS for the current fiscal year.
The company also recently declared a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Monday, August 14th will be issued a dividend of $0.28 per share. The ex-dividend date is Thursday, August 10th. This represents a $1.12 dividend on an annualized basis and a dividend yield of 0.59%. This is a positive change from Chemed Corp.’s previous quarterly dividend of $0.26. Chemed Corp.’s payout ratio is currently 28.07%.
Several equities research analysts have recently weighed in on CHE shares. BidaskClub downgraded Chemed Corp. from a “buy” rating to a “hold” rating in a report on Wednesday, August 2nd. Royal Bank Of Canada reissued a “hold” rating and issued a $208.00 price objective on shares of Chemed Corp. in a research note on Wednesday, July 5th. Zacks Investment Research raised Chemed Corp. from a “hold” rating to a “buy” rating and set a $226.00 price objective on the stock in a research note on Friday, July 28th. Oppenheimer Holdings, Inc. increased their price objective on Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a research note on Thursday, July 27th. Finally, TheStreet cut Chemed Corp. from a “b+” rating to a “c+” rating in a research report on Tuesday, July 25th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. Chemed Corp. currently has a consensus rating of “Hold” and a consensus price target of $218.33.
In other news, insider Kevin J. Mcnamara sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, July 28th. The shares were sold at an average price of $201.16, for a total transaction of $3,017,400.00. Following the sale, the insider now owns 173,801 shares in the company, valued at $34,961,809.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director George J. Walsh III purchased 1,000 shares of the business’s stock in a transaction dated Monday, June 26th. The shares were purchased at an average price of $204.56 per share, for a total transaction of $204,560.00. Following the acquisition, the director now directly owns 7,908 shares of the company’s stock, valued at $1,617,660.48. The disclosure for this purchase can be found here. 5.32% of the stock is owned by insiders.
About Chemed Corp.
Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.
Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with our FREE daily email newsletter.